IgG autoanti-IgE is detectable in the serum of individuals with enhanced IgE production, namely those with allergic conditions such as asthma,1-4 and with parasitic infestations. The method used for constructing the fibroblast cell line transfected with the oc and y subunits of the human FccRI (CHKIE1) and the original untransfected cell line (CHO) is described elsewhere." CHO was cultured in Iscove's modified Dulbecco medium (IMDM) containing 10% heat inactivated fetal calf serumh (FCS) (Seralab, JRH Biosciences) and 100 U/ml penicillin + 100,g/ml streptomycin.
CHKIE1 cells were cultured in IMDM, 10% FCS, and 1 mg/ml gentamicin (Gibco, Life Technologies). Both cell lines were cultured to confluence and split every three days. PBS containing 0 05% trypsin/0-02% EDTA (Gibco, Life Technologies) was used to detach the cells from the bottom of the culture flask. Cells were washed in PBS containing 1% bovine serum albumin (BSA) and then resuspended to a concentration of 106 per ml.
EXPRESSION OF FC£RI Oa CHAIN ON THE CHKIEI CELLS
A 100 pl volume of 10 g/ml FITC labelled IgE or IgG was incubated for 15 minutes at room temperature with 100,l of either CHK1E1 or CHO cells (106 cells per ml) and 100 tl of PBS containing 0-1% BSA, and then washed with 2 ml ofPBS containing 0 1 % azide (to prevent capping). Unlabelled IgE was used to assess autofluorescence. The cells were resuspended and fixed in 0-3 ml Sysmex cellpack containing 0-5% formaldehyde. They were collected on a FACScan (Becton Dickinson) with a linear fluorescence setting of 660 volts. The fluorescence (FL1) profile versus forward scatter (FSC) was used to monitor the cells, and the amplification scale was (fig 1 B) (fig 1C) . unlikely to be much higher in asthma patients who show moderate increases in circulating levels ofIgE compared with, for instance, atopic eczema patients. It is therefore important to note that the inhibition values presented in this paper were obtained using IgE-FITC to oc chain ratio (giving 50% saturation of receptors) at least 10-fold higher than those found in vivo. We are also likely to have used a much higher IgE to anti-IgE ratio than is the case in the human circulation.16
The demonstration that human autoanti-IgE blocks the binding of IgE to its high affinity receptor in vitro is very much in accord with the recent work of Hellman,9 who showed that the induction of an autoanti-IgE response in rats, by immunisation with a recombinant Ce2-CO3 fragment, abrogated in vivo mast cell activation. We have also shown previously that autoanti-IgE antibodies isolated from asthma patients modulate allergen induced basophil histamine release.'7 Taken together, these data suggest that the stimulation of autoanti-IgE production, particularly those directed against the C£2-C£3 interdomain region,7 has therapeutic potential in allergic individuals. The great attraction of this strategy is that therapy is aimed at stimulating the production of a naturally occurring, rather than a novel, antibody.
